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Abstract
Introduction: The etiology of ovarian cancer is largely unknown. One hypothesis is that the inefficient removal of the blood
clots and fibrin products which are deposited in the vicinity of the ovary by retrograde menstruation might be associated
with an increased risk of ovarian cancer. Several single nucleotide polymorphisms within genes which comprise the
fibrinolytic system have been shown to have functional effects on the rate of blood clot degradation. These were
considered to be candidate genes in the present study.
Aim: We studied the genotype distributions of 12 functional SNPs of four genes (tPA, uPA PAI1 and TAFI) among 775
ovarian cancer cases and 889 controls.
Results: No significant associations were seen between any of the ten SNPs and the risk of ovarian cancer as a whole, or in
any histologic subgroup.
Discussion: Germline known functional variants of genes in the fibrinolytic system are not associated with risk of ovarian
cancer.
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Introduction
Although the cause of ovarian cancer is unknown, various risk
factors appear to be related to reproduction, contraception and
inflammation. Parity, breast-feeding, oral contraceptives and tubal
ligation are all protective. In contrast, endometriosis and talc are
among the few known risk factors. On the whole, these
observations suggest that factors which diminish the number of
ovulatory cycles are protective and factors that increase local
inflammation may be carcinogenic.
Endometriosis is associated with a significantly increased risk of
ovarian cancer [1,2]. The prevalence of endometriosis in patients
with epithelial ovarian cancer is 36% for clear cell carcinoma and
19% for endometrioid ovarian carcinoma. In one study, ovarian
cancer was found in5–10%ofovarian endometriotic lesions[3]. It is
believed that retrograde menstruation is necessary for the develop-
ment of endometriosis [4]. Tubal ligation and oral contraceptives
prevent (or reduce) retrograde menstruation and both are associated
with a reduction in the risk of ovarian cancser [5–8].
Despite the high prevalence of retrograde menstruation in up to
90% of women [9,10], the prevalence of endometriosis is
estimated to be in the range of 7–10% of women of reproductive
age. One speculative explanation for this discrepancy is that an
intact fibrinolytic process clears blood clots and endometrial cells
from pelvic structures. We hypothesise that women with a
defective fibrinolysis system may not remove blood clots effeciently
and, as a result, this increases the time that endometrial cells in
menstrual blood clots remain in contact with pelvic structures.
These cells might possibly implant on the peritoneal or ovarian
surface[11]. If this hypothesis is correct, there may be an
association between defective fibrinolysis and the risk of ovarian
cancer.
The fibrinolytic system comprises a family of proteins that
includes two plasminogen activators (urokinase-type plasminogen
activator (uPA) and tissue-type plasminogen activator (tPA)), the
zymogen plasminogen, the active form plasmin, and inhibitor
proteins like plasminogen activator inhibitor type 1 (PAI1) and
thrombin-activated fibrinolysis inhibitor (TAFI).
The tPA is the primary mediator of local intravascular
fibrinolysis. Genetic factors play a role in the variation of
endothelial t-PA release [12]. The c.27351C.T variant
(rs2020918) within the enhancer region of the t-PA gene is
strongly correlated with endothelial t-PA release rates. This SNP is
associated with an increased risk of myocardial infarction [13].
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5918Elevated levels of uPA promote tumor cell spread and
metastasis and are associated with relatively poor prognosis [14].
A functional polymorphism of the uPA gene has been described.
This is a substitution of C to T in the nucleotide sequence of exon
6 encoding the kringle domain resulting in Pro to Leu replacement
at codon 141 (rs2227564).
PAI1 is a serine protease inhibitor that binds to both
plasminogen activators, t-PA and u-PA, forming a stable complex
that is cleared from the circulation by hepatic cells [15]. High
levels of PAI1 are a common finding in ovarian cancer [16]. PAI1
over-expression is also associated with poor survival in ovarian
cancer patients [17–19]. Furthermore, it has been suggested that
PAI1 levels are important in the prognosis of breast and cervical
cancers [20–22]. In cancer transplantation models, tumor growth,
invasion, and angiogenesis are diminished in PAI1- deficient mice
[23,24]. Several single nucleotide polymorphisms (SNPs) in the
PAI1 gene have been associated with a significant increase in PAI1
protein expression [25].
Thrombin-activated fibrinolysis inhibitor (TAFI) is a potent
inhibitor of fibrinolysis that removes carboxy terminal–lysine
residues from partially-degraded fibrin and decreases plasminogen
binding [26]. In vivo animal studies demonstrate that inhibition of
TAFI activity by carboxypeptidase increases thrombolysis [27].
Circulating levels of TAFI are strongly controlled by six
polymorphic variations in the promoter and the 3’UTR region
of the TAFI gene [28].
We propose that functional variants in these genes may be
related to ovarian cancer risk. The objective of the present study
was to determine if any of known functional polymorphisms of
these four genes of the fibrinolytic system are associated with an
increased risk of invasive ovarian cancer.
Materials and Methods
Study Population
Cases were ascertained through the Ontario Cancer Registry.
All women newly diagnosed with invasive epithelial ovarian cancer
in Ontario, Canada, from January 1995 to December 1999 were
eligible. Of 1694 potentially eligible cases, 1016 women consented
and provided blood samples for DNA testing. There were 775
women for whom both a DNA sample and sufficient clinical
information were available and these are the subjects of the
current study. Patients were categorized in four ethnic groups of
Caucasian; French Canadian, East Asian and Indian (table 1).
One thousand sixty-three controls were selected from healthy
women who attended a screening clinic for well-women at the
Women’s College Hospital, Toronto, between 1996 and 2001. Of
the women who were approached to participate in this study,
approximately 80% agreed and provided a blood sample and
completed a risk factor questionnaire. All study subjects provided
informed consent for genetic testing. Controls had not been
diagnosed with cancer. Study subjects were asked to provide
details about their ethnic origins, including information about the
place of birth of their four grandparents. 889 of these healthy
women who were from the four ethnic groups of the cases were
enrolled in this study.
We analyzed DNA samples from 1664 subjects, 775 cases with
ovarian cancer and 889 controls. Patients known to carry a
BRCA1 or BRCA2 mutation were excluded. Table 1 provides
demographic information on the cases and controls.
Genotyped Variants
Each DNA sample was checked for a total of 12 SNPs in the
four candidate genes. All these 12 variants were shown to affect the
expression or function of their related gene or protein [13,25,28].
These variants include rs2020918 (c.27351C.T) from tPA gene;
rs2227564 (Pro141Leu) from uPA gene; rs1799889, rs2227631,
rs2227674 and rs6465787 from PAI1 gene; and rs1926447
(Thr347Ile), rs3581491, rs2146881, rs3742264 (Ala169Thr),
rs1087 and rs34813434 from TAFI gene.
iPLEX chemistry on a MALDI-TOF MassARRAY system
(Sequenom Inc., San Diego, CA, USA) was used for genotyping
the 12 SNPs in eight reactions. The procedures were performed
according to the manufacturer’s standard protocol [29].
Statistical methods
Deviations of genotype frequencies in the controls from those
expected under Hardy Weinberg equilibrium (HWE) were
assessed by x
2 tests (1 degree of freedom). All case-control
comparisons were adjusted for age and ethnicity, using multivar-
iate logistic regression and the adjusted P-values and odds ratios
(OR) were reported. Given the number of comparisons in this
study, a p-value of ,0.01 was used as the criterion of statistical
significance. Associations between ovarian cancer and SNP
genotypes were measured in the study group as a whole and then
in subgroups defined by histological type, age of diagnosis and
family history. Family history was defined as one or more first- or
second-degree relatives with breast cancer under age 50 or ovarian
cancer.
Results
Twelve SNPs, representing four genes were examined in 775
ovarian cancer cases and 889 controls. Two SNPS in TAF1
(rs1087 and rs34813434) were excluded because of call rates below
90%. The call rates for the other 10 SNPs were all in excess of
95% and all were in Hardy-Weinberg equilibrium among
controls. The genotypes for these ten SNPs are shown in table 2.
For none of the 10 studied SNPs was the distribution of
genotypes significantly different between the cases and controls
(table 2). Sub-division of cases based on the age at diagnosis or
histological type did not yield any significant association (data not
shown).
Table 1. Subject characteristics of the ESCC cases and
controls.
Variable Cases Controls P-Value
Total Number, n 775 889 –
Age, Mean (range)
57.8
(26–79)
56.3
(28–94) 0.003
Ethnicity, n (%) Caucasian 654 (84.4) 814 (91.5) 0.0002
French-Canadian 77 (9.9) 65 (7.3)
East Asian 33 (4.3) 5 (0.6)
Indian 11 (1.4) 5 (0.6)
Histology, n (%) Serous 407(52.5) – –
Endometrioid 176 (22.7) –
Mucinouse 73 (9.4) –
Clear Cell 49 (6.3) –
Other 70(9.1) –
doi:10.1371/journal.pone.0005918.t001
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We hypothesized that an inherited defect in the fibrinolytic
pathway could lead to an increased duration of exposure of the
ovaries to blood clots containing epithelial cells originating from
the Mullerian tract deposited by retrograde menses, and thereby
increase the risk of ovarian cancer. This hypothesis was based on
the known protective effect of tubal ligation and oral contracep-
tives against ovarian cancer, which prevent or reduce retrograde
menstruation. In addition, previous research has demonstrated an
increased activity of inhibitors of the fibrinolytic system in ovarian
cancer patients. Despite the large number of samples and SNPs
examined, the results of the present study were negative. The
ovarian cancers that have been most strongly associated with
Table 2. Genotypes of the 11 functional variants of 4 genes on the 775 cases and 889 controls.
Variant Gene MAF* Cases, n (%) Controls, n (%) OR{ P-Value{
rs2020918 tPA 0.34
C/C 532 (70.8) 647 (73.4) 1.00 1.00
C/T 206 (27.4) 219 (24.8) 0.95 0.60
T/T 13 (1.8) 16 (1.8) 1.07 0.37
Pro141Leu uPA 0.25
Pro/Pro 427(55.3) 496 (55.8) 1.00 1.00
Pro/Leu 300 (38.9) 340 (38.2) 1.00 0.97
Leu/Leu 45 (5.8) 53 (6.0) 1.00 0.97
rs1799889 PAI1 0.46
4G4G 226 (29.3) 257 (28.9) 1.00 1.00
4G5G 372 (48.2) 440 (49.5) 0.96 0.71
5G5G 174 (22.5) 192 (21.6) 1.02 0.82
rs2227631 PAI1 0.41
A/A 260 (33.9) 315 (35.5) 1.00 1.00
A/G 362 (47.3) 425 (47.9) 1.03 0.79
G/G 144 (18.8) 148 (16.6) 1.08 0.27
rs2227674 PAI1 0.21
A/A 452 (59.7) 558 (63.0) 1.00 1.00
A/G 268 (35.4) 295 (33.3) 1.12 0.30
G/G 37 (4.9) 33 (3.7) 1.17 0.20
rs6465787 PAI1 0.01
C/C 749 (97.0) 866 (97.4) 1.00 1.00
C/T 23 (3.0) 22 (2.5) 1.17 0.62
T/T 0 (0.0) 1 (0.1) – –
Thr347Ile TAFI 0.30
Thr/Thr 374 (48.6) 450 (50.6) 1.00 1.00
Thr/Ile 327 (42.5) 354 (39.8) 1.12 0.29
Ile/Ile 69 (8.9) 85 (9.6) 0.97 0.73
rs35814191 TAFI 0.34
C/C 314 (43.0) 388 (43.8) 1.00 1.00
C/2 320 (43.8) 396 (44.7) 1.06 0.57
2/2 96 (13.2) 101 (11.5) 1.10 0.24
rs2146881 TAFI 0.26
G/G 398 (55.0) 482 (54.6) 1.00 1.00
G/A 277 (38.3) 335 (37.9) 0.99 0.90
A/A 49 (6.7) 66 (7.5) 0.93 0.44
Ala169Thr TAFI 0.32
Ala/Ala 346(46.3) 392 (44.3) 1.00 1.00
Ala/Thr 324 (43.4) 405 (45.8) 0.96 0.68
Thr/Thr 77 (10.3) 88 (9.9) 1.00 0.96
*Minor Allele Frequency.
{P-value and odds ratio (OR) are adjusted for age and ethnicity using multivariate logistic regression analysis.
doi:10.1371/journal.pone.0005918.t002
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Notably, in neither of these subgoups was an association found.
Increased expression of several fibrinolytic modulators has been
associated with increased risk for cancer development and poor
prognosis [14–24]. Specifically, PAI1 was shown to promote
tumor growth in a dose dependent and stage-dependent manner
[30]. Moreover, the SNP rs1799889 in the promoter of the PAI1
gene was shown by 37 separate studies to poses a significant allelic
dose-dependent correlation between the 4G allele and increased
PAI1 protein level in vivo. The 4G/4G homozygotes have the
highest levels of circulating PAI1 [26].
Sternlicht et al [25] detected an association between PAI1 levels
and overall survival from breast cancer in a study of 2,539 cases
and 1,832 controls. However, the PAI1 4G/5G SNP was not
associated with breast cancer incidence, clinical outcome or PAI1
expression. These authors concluded that cancer–associated
signals are more important than germline genetic variability in
determining the expression of PAI1 in breast cancer patients. In
our study, the 4G/4G, 4G/5G and 5G/5G genotypic distribu-
tions were similar in the cases and controls.
We included all the SNPs of genes of the fibrinolytic system that
were found to be associated with a change in either the
concentration of the protein or its function.
We failed to detect any significant association between
fibrinolysis gene polymorphisms and the incidence of ovarian
cancer in any histological subtype. If the fibrinolytic pathway is
involved in ovarian cancer, the risk does not appear to be
influenced by functional polymorphisms in the key genes.
However, given the previous studies, which report a possible role
for these enzymes in the initiation or progression of cancer, it may
be that variation in the expression of the proteins in the fibrinolytic
system remains relevant for ovarian carcinogenesis.
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